Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
you can always click your ruby slippers if it doesn't work. good luck!
Just follow the yellow brick road Dorothy and when you wake up you will be back in Kansas again. "But it seemed so real"
surprised this is still so low
unfortunately, probably more folks will be heading for the exit if it's confirmed that they're "going dark"...
broke through both the 50 ($13.70) and 200 MDA ($13.47) today
maybe Hale converted the remaining debt to shares after all for their 'future plans' (once silver takes off)? Do you know how to confirm this, NYBob? I have only been able to find the "notice of intent" on SEDAR & Hale would not answer a direct inquiry. Also, someone is consistently sucking up shares at the bid on the OTC where it still trades (USCZF). intriguing....
how is that shorting strategy working out for you ?
from your earlier post, when did Cantor Fitzgerald say SGYP's funds will run out again? can you remind me? end of the year, was it ?
is that why it's tanking ??
Now everyone is waking up to it all of a sudden LOL. this may be the last dip to sub$ for a while IMHO
this one's still under the radar & totally undervalued, in my humble opinion. I liked their presentation from the July shareholders' meeting.
http://www.fnr.ca/images/file/NR%202014/49%20North%20AGM%20July%202014.pdf
still hoping for the $ 8 PPS here ?
hoping for $ 2 for SGYP as well ? at least that might have a higher chance of coming true LOL
oops. "temporary bottom" it was, I guess...
no rush. "better" prices coming....convertible debt note signed :
http://archive.fast-edgar.com//20140829/AE2ZN22CL222K27V222A2WX2MRPBZ222ZG62/
now below the PPS they were at before the 1-for-8 reverse split in Feb 2013. wonder whether another one is in the cards here before long...
you're right. maybe a little averaging down is in order during tax loss selling season...
personally, I wouldn't mind, in case the tech deal should happen, if the other party would get majority control of WOLV & refocus on cyberspace security, at least for the near/mid term; - would probably work out better for the shareholders, in my humble opinion only, of course...
compare the 1 yr charts of IRWD and SGYP.
I like the IRWD "trend" better :)
LOL. let's hope...
Brutal day , for SGYP as well (-2.8%), agree. Looks like the shorts are hard at work again...
looks like someone's trying to 'build a chart'
can't wait to see what happens EOY in tax loss harvesting season
not gonna happen. the option market should give you a clue...but apparently the hay's not hanging low enough yet for this horse to get it ...
http://finance.yahoo.com/news/trade-sees-ironwood-solid-ground-160737834.html
This one's a no-brainer, IMHO. The isolation chemistry outlined in that recent report speaks volumes, to a chemist, anyway. Also, it seems to me that the Nb & Ta assets are not assigned any value by the market right now ?? Wish I had more...
Actually, the SGYP picture is the really grim one - stock price ~40% down since March, continual dilution, only 2Q of operating expenses left in the bank, years away from a product on the market (if ever), no interest in buyout / partnership on the horizon --- LOL how much more grim can it get ??
read the JP Morgan article again:
http://seekingalpha.com/article/2222433-j-p-morgans-geoff-meacham-plucks-biotechs-with-upside-from-a-down-market
even if they would ever make it to the market (2017 at the earliest), which I doubt, the only way they could ever compete with IRWD is on price (says JP Morgan).
If you look at the structure/complexity/size of both synthetic peptides, and all natural amino acid building blocks in both (plecanatide + linaclotide), an educated guess would probably place the drug manufacturing costs in the same ball park for both companies.
Since the Synergy drug seems to require at least 10x (maybe even more) the dose to touch linaclotide in terms of efficacy, the chances of Synergy to compete in terms of price, in my opinion, are zero, nada, none.
no wonder no one wants to buy them...
...you forgot to add "in my personal opinion"
...how about the one JP Morgan voiced three months ago taking into account the Synergy trial results to date?
I'll take my chances with JP Morgan, thank you very much.
(quote): "...Synergy Pharmaceuticals Inc.is starting two Phase 3 trials with its constipation drug candidate, plecanatide, which would be a competitor to Linzess. Does that put pressure on Ironwood?
GM: Our view is that it doesn't, for a couple of reasons. The first is that the theoretical differentiation for the Synergy drug was that it would have a lower rate of diarrhea, which is one of the most common adverse events with Ironwood's Linzess. The efficacy was presumed to be equal. What we know now, from Phase 2/3 trials, some released last year, is that for diarrhea, plecanatide looks largely similar. It is not differentiated in that respect. Its efficacy is not exactly equal. It's going to be difficult to market a drug like plecanatide in a primary care setting when it isn't any different from Linzess. ..."
quote from:
http://www.hispanicbusiness.com/2014/5/16/j_p_morgan_s_geoff_meacham.htm
What does 'the street' say about Synergy, with zero income, cash running out in 2 quarters, vulnerable IP position & no partnership on the horizon ??
Just curious ..,
actually, I was correcting your lies remember LOL
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105337674
why don't we compare notes towards the end of the year, see how things play out for IRWD, and if SGYP actually manages to stay afloat, despite their desperate financial situation...
Uh, new AGA guidelines for IBS treatment were over your head, dude ?
and the UHC step edit coverage that favors the IRWD drug over Amitiza escaped your notice as well?
They have revenue & a product on the market. Synergy has no revenue, is years away from having a product on the market, and has only 2 Quarters of Operating expenses left in the bank , so says Cantor Fitzgerald; you posted it yourself, remember ? And that would be 'superior' to IRWD how, exactly ??
An Ironwood formulation patent that is expected to extend LINZESS® Patent Protection Through 2031 (see: http://news.ironwoodpharma.com/Press-Releases/Ironwood-Receives-Notice-of-Allowance-for-Methods-of-Use-Formulation-Patent-Expected-to-Extend-LINZE-f1.aspx)
has just been issued (Aug 15, 2014): http://www.4-traders.com/IRONWOOD-PHARMACEUTICALS-5933097/news/Ironwood-Pharmaceuticals--Forest-Laboratories-Holdings-Assigned-Patent-18907216/
Also, before you spread lies, it would behoove you well to read up on the company & the facts:
the brand is actually approaching profitability after only about 18 months (and there has never before been an example of a biotech successfully launching a primary care drug, so that alone is quite a feat)!
There is strong demand for Linzess(R): prescriptions jumped 36% from 1Q to 2Q 2014. With regard to refill rate: there is strong patient persistence, tracking 40-65% ahead of launch analogues, see the IRWD Q2 2014 Investor Update from Aug 4, 2014:
http://investor.ironwoodpharma.com/common/download/download.cfm?companyid=ABEA-45DU4J&fileid=773700&filekey=ca1eef29-983d-41ff-a376-c377e858a3a6&filename=IRWD_Q214.InvestorUpdate.pdf
if you haven't fallen off the learning curve completely & want to try to understand why the institutional ownership in IRWD is so high - this is a good starting point:
http://www.gastrojournal.org/article/S0016-5085(13)01529-1/pdf
you failed to read between the lines. nothing but a paid shill trying to keep up morale, since they're the ones having to sell all the SGYP shares to (try to) keep them afloat, remember?
and you keep forgetting : at an ever decreasing share price:
SGYP Mar 13, 2014: $6.07
this morning : $3.63 (-40%)
IRWD Mar 13, 2014: $12.74
today: $13.07 (+2.6%)
maybe you didn't pay attention ?
looks like Cantor Fitzgerald is slowly changing their tune. Formerly extremely bullish, even they acknowledge now that SGYP is going to run out of cash ~ EOY 2014 and admit that only a (highly speculative) M&A scenario justifies their price target, read their release again:
(quote): ..."We continue to view Synergy as a likely takeout candidate and base our PT on an M&A valuation. We reiterate our BUY rating but acknowledge that there is a temporary financing overhang on the stock since the company has approximately two quarters of cash remaining.”
riddle me this... - if they're so attractive, why has no buyer shown up yet ?? and since all the super data for the "best in class" drug has not attracted a buyer until now, why would one show up now 2Q before they run out of cash ?
here's a hint for the slow learner class (the one you're enrolled in, so pay attention !):
it's the SAME REASON why there isn't a single institutional investor with more than ~$18 million in Synergy, whereas the largest institutional investor in IRWD put ~$250 million on the table...
http://www.nasdaq.com/symbol/sgyp/institutional-holdings
http://www.nasdaq.com/symbol/irwd/institutional-holdings
amitiza reps whining about the new UHC step edit coverage ...writing's on the wall
(see also new AGA guidelines IBS treatment )
http://www.cafepharma.com/boards/showthread.php?t=562537
wait, watch & learn
again, I can explain it to you (from 50 different angles), but I can't UNDERSTAND it for you :)
SGYP Mar 13, 2014: $6.07
today : $3.53 (-42%)
IRWD Mar 13, 2014: $12.74
today: $13.40 (+1%)
'nuff said
SGYP Mar 13, 2014: $6.07
today : $3.53 (-42%)
IRWD Mar 13, 2014: $12.74
today: $13.40 (+1%)
Dream on
SGYP 6 mo ago (Feb 6, 2014): $ 5.07
SGYP today (open on Aug 6, 2014): $ 3.61 (-29%)
IRWD 6 mo ago (Feb 6, 2014): $ 12.32
IRWD today (open on Aug 6, 2014): $ 13.60 (+10%)
which story creates value ?
what does the market think ?
2014 Q2 IRWD Earnings Call Transcript with Analysts Q/A session :
http://seekingalpha.com/article/2172563-ironwoods-ceo-discusses-q1-2014-results-earnings-call-transcript
Nope. they've written off the Abigail/Lac Kame and EM-1 Properties in Canada.
quote from 10Q filed 07/21/2014:
"a. Lithium Properties
The Company was exploring lithium deposits in the Abigail Lithium Property located in the James Bay region of Quebec, Canada. As of May 31, 2014, the elected to not renew the 95 map-designated cells totaling approximately 5,000 hectares. In addition, the Company’s 12 map-designated cells just north of the Abigail property named Lac Kame and 25 map-designated cells named EM-1 have expired and have not been renewed. On August 31, 2013, management decided to fully write down the capitalized cost of Abigail property, based on the management’s decision to not further renew the claims upon their expiration between November 2013 to November 2014."
"In October 2013, the Company elected to drop 83 Abigail claims and currently holds 95 Abigail claims. In May and June 2014 the Company elected to drop the remaining 95 Abigail claims."
"Lac Kame and EM-1Properties, Quebec
In addition to the Abigail Property, the Company closed an Lac Kame and EM-1 Purchase Agreement to acquire a One Hundred (100%) interest in two mining properties known as the Lac Kame and EM-1 both located in the James Bay, Quebec region of Canada. It is covered by NTS sheets 32O13. The property is made up of 37 map-designated cells totaling 1,961 hectares. The Company's main interest with the newly acquired claims will be magnetic anomalies for kimberlite based upon the airborne magnetic survey released in October 2011. The Company planned on raising an addition $150,000 to commence an initial exploration campaign designed to discover the precise location of drill test targets identified by the aireborne electromagnetic (“EM”) data. Each identified target will be surveyed with ground EM instruments to insure that the character of the anomaly is consistent with known kimberlites. The Company elected to let these claims expire in November 2013."
http://www.sec.gov/Archives/edgar/data/1424455/000121390014005030/f10q0514_rimrockgold.htm